Selpercatinib Shifts Treatment Paradigm for MTC and NSCLC
- PMID: 37874126
- DOI: 10.1158/2159-8290.CD-ND2023-0011
Selpercatinib Shifts Treatment Paradigm for MTC and NSCLC
Abstract
In separate trials, the RET inhibitor selpercatinib showed superiority over standard of care in RET-mutated medullary thyroid cancer and in RET fusion-positive non-small cell lung cancer-although researchers say more follow-up is needed. The findings highlight the importance of tumor sequencing.
©2023 American Association for Cancer Research.
Comment on
-
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870973 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical